Gegen Krebs Gerichtet Chimäre Antigenrezeptoren

Details

Veröffentlichungs-Nr.

EP4725503

Anmeldetag

29. März 2017

Veröffentlichung

15. April 2026

Rechtsraum

EP

IPC

A61K40/42(UNIV NORTH CAROLINA et al.)(UNIV PENNSYLVANIA et al.)

Abstract

Provided herein is a composition comprising, a cell, comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains. Also provided herein are methods for treating diseases using the compositions described herein. Further provided herein is a kinase inhibitor for use in therapeutic methods described herein.

Anmelder

Firma

University Of Southern California

Land

🇺🇸 USA